Aura Biosciences Inc
NASDAQ:AURA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
YEDIGITALCorporation
TSE:2354
|
JP |
|
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
|
IN |
|
C
|
Compania Electrica del Litoral SA
SGO:LITORAL
|
CL |
|
Graco Inc
NYSE:GGG
|
US |
|
Bialetti Industrie SpA
MIL:BIA
|
IT |
Aura Biosciences Inc
Total Assets
Aura Biosciences Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aura Biosciences Inc
NASDAQ:AURA
|
Total Assets
$169.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$134B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$59B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$25.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$40.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
Aura Biosciences Inc
Glance View
Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).
See Also
What is Aura Biosciences Inc's Total Assets?
Total Assets
169.4m
USD
Based on the financial report for Dec 31, 2025, Aura Biosciences Inc's Total Assets amounts to 169.4m USD.
What is Aura Biosciences Inc's Total Assets growth rate?
Total Assets CAGR 5Y
50%
Over the last year, the Total Assets growth was -7%. The average annual Total Assets growth rates for Aura Biosciences Inc have been -9% over the past three years , 50% over the past five years .
